NEW YORK (TheStreet) -- IsoRay (ISR) - Get Report surged Wednesday after the company announced significant results for its cesium-131 isotope in early clinical interstitial implants for gynecologic malignancies.
The first major published peer study showed improved results with IsoRay's cesium-131 seeds in treating gynecological cancer. The study found 84.4% local control with a 12 month median follow-up, which surpassed other previously published rates of 33% and 63%.
"We are very excited to have our Cesium-131 isotope seeds chosen for use in the treatment of gynecologic cancers," said CEO Dwight Babcock in a statement. "We believe our marketing is most successful by teaming up with medical industry thought leaders as they seek better solutions and outcomes for their patients. As we continue to develop our product offerings internally with support from industry leaders, our message is clear and the medical community is becoming increasingly aware of the innovative alternative our Cesium-131 products offer to cancer patients."
The stock was up 34.95% to $2.51 at 10:29 a.m. on Wednesday.
Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.